The Week in Review: China Pharma Investment, Company Progress

Pfizer has built a Shanghai-based business development team to take advantage of the consolidation it expects over the next few years; the Changzhou Biopharmaceutical Incubator began construction of its $76 million project; Morningside Asia Venture will form a China JV with Can-Fite BioPharma to develop a liver cancer drug; China Pharma Holdings has asked for SFDA approval of a generic anti-hypertension drug; China Sky One Medical (中国天字一号医药公司) will turn its focus toward injected generic western drugs; Sinovac Biotech (北京科兴生物制品有限公司) expects to beat 2009 forecasts and will issue additional shares; Sinobiopharma reported greatly improved financial results for its Q2; Shandong Luoxin Pharma listed its ADRs on the QX tier of the OTC Exchange; and Burdica Biomed will have Sinopharm register its products in China and distribute them. More details... Stock Symbol: (NYSE: PFE) (TASE: CFBI) (NYSE: CPHI) (NSDQ: CSKI) (NSDQ: SVA) (OTCBB: SNBP) (HKEX: 8058; OTCQX: SLUXY)